Plasma Peptidome Pattern of Breast Cancer Using Magnetic Beads-Based Plasma Fractionation and MALDI-TOF MS: A Case Control Study in Egypt

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 20; no. 1; pp. 175 - 184
• Main Authors: Zaki, Ahmad, Ramadan, Ragaa Abdelkader, Moez, Pacint, Ghareeb, Hala, Elkarmouty, Ahmad
• Format: Journal Article
• Language: English
• Published: Thailand West Asia Organization for Cancer Prevention 01-01-2019
• Subjects: Breast Neoplasms - blood; Breast Neoplasms - metabolism; Case-Control Studies; Chemical Fractionation - methods; Down-Regulation - physiology; Egypt; Female; Humans; Middle Aged; Peptides - blood; Proteome - metabolism; Proteomics; Sensitivity and Specificity; Software; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods; Up-Regulation - physiology; Egypt; Matrix assisted laser desorption ionization/ time of flight mass spectrometry; ClinProTools; magnetic beads
• DOI: 10.31557/APJCP.2019.20.1.175
• EISSN: 2476-762X
• ISSN: 1513-7368

Objective: The present study aimed to determine peptidome patterns in breast cancer (BC). Methods: We analyzed
the plasma proteomic profiling of 80 BC patients and 50 healthy controls, using hydrophobic interaction chromatography
magnetic beads (MB-HIC8) separation followed by Matrix assisted laser desorption ionization/ time of flight mass
spectrometry (MALDI-TOF MS). Results: ClinProTools software identified 92 peaks that differed among the analyzed
groups, 33 peaks were significantly different (P < 0.05). Of those, 22 peaks were up-regulated while 11 peaks were
down-regulated in BC patients compared with the healthy controls. Three peptide ion signatures (m/z 1,570.31, 1,897.4
and 2,568.17) were provided by the Quick Classifier model to discriminate BC patients from healthy control subjects
with 96.4% accuracy. External validation was performed by an independent group and this achieved a sensitivity of
100% and a specificity of 76.9%. Conclusion: MALDI-TOF MS has good analytical performance in distinguishing
BC patients from healthy controls.